指南对比:PSMA PET 在中危前列腺癌初始分期中的应用
本文系统回顾并对比了 EAU、AUA、NCCN、NICE、CUA、ASCO、SNMMI 等机构关于 PSMA PET 用于新诊断中危前列腺癌分期的指南。各指南对中危患者是否使用 PSMA PET 存在明显分歧,而对高危患者使用 PSMA PET 的共识更强。相关推荐多为弱推荐且基于专家意见,领域仍在研究中,指南可能随新证据更新。
要点
- 各指南对中危前列腺癌是否行 PSMA PET 分期意见不一。
- 高危前列腺癌使用 PSMA PET 分期的共识更强。
- 现有推荐多为弱推荐,主要基于专家意见。
核心结论
- 支持新诊断前列腺癌使用 PSMA PET 的证据在增加,但中危患者使用存在明显分歧。
- 相关推荐普遍较弱且基于专家意见,指南可能随新证据变化。
研究设计与样本
- 综述类研究,检索并批判性分析 EAU、AUA、NCCN、NICE、CUA、ASCO、SNMMI 的英文指南与推荐。
主要发现
- 各指南对 PSMA PET 是否作为新诊断中危前列腺癌分期工具有显著分歧。
- 对高危前列腺癌使用 PSMA PET 分期的共识更强。
临床怎么用
- 中危前列腺癌是否行 PSMA PET 分期需结合具体指南与临床情境个体化决策。
- 高危患者可更积极考虑 PSMA PET 分期。
局限性
- 推荐多为弱推荐且基于专家意见。
- 领域仍在研究中,指南可能随新证据改变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To provide a comprehensive review and analysis of guidelines from various professional and medical organisations regarding the use of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) as a staging scan for men with newly diagnosed intermediate-risk prostate cancer (PCa). MATERIALS AND METHODS: English-language guidelines and recommendations from the following associations and societies were reviewed and critically analysed: European Association of Urology (EAU), American Urological Association (AUA), National Comprehensive Cancer Network (NCCN), National Institute for Health and Care Excellence (NICE), Canadian Urological Association (CUA), American Society for Clinical Oncology (ASCO), Society for Nuclear Medicine and Medical Imaging (SNMMI). RESULTS: There is significant disagreement among guidelines regarding whether PSMA PET is a useful staging tool for men with a new diagnosis of intermediate-risk PCa. There is a stronger consensus that PSMA PET is useful in staging high-risk PCa. CONCLUSION: Whilst there is a growing body of evidence that supports the use of PSMA PET in newly diagnosed PCa, there is significant disagreement regarding its use for men with intermediate-risk disease. Recommendations are generally weak and based on expert opinions. This is an area of considerable ongoing research, and guidelines are likely to change as new evidence emerges.
引用
- Carll J, Shi W, Perera M, et al. Guideline of guidelines: PSMA PET in staging newly diagnosed intermediate-risk prostate cancer. BJU Int. 2025. PMID: 40704877. doi:10.1111/bju.16872
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。